High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population

被引：75

作者：

García-Martín, E

Martínez, C

Ladero, JM

Gamito, FJG

Agúndez, JAG

机构：

[1] Univ Extremadura, Sch Med, Dept Pharmacol, E-06071 Badajoz, Spain

[2] Univ Extremadura, Sch Biol Sci, Dept Biochem, E-06071 Badajoz, Spain

[3] Univ Complutense Madrid, San Carlos Univ Hosp, Serv Gastroenterol, Madrid, Spain

[4] Hosp Insalud, Surg Serv, Merida, Spain

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2001年 / 57卷 / 01期

关键词：

CYP2C9; genotype; allele frequency;

D O I：

10.1007/s002280100264

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective: To search for ethnic variability in the impact of cytochrome P-450 2C9 (CYP2C9) polymorphism. Methods: CYP2C9 allelic variants related to impaired CYP2C9 metabolism were analysed in genomic DNA from 157 Spanish healthy subjects using amplification-restriction and sequencing procedures. Results: The frequency for CYP2C9 mutated alleles is higher among the Spanish subjects analysed than that reported for other Caucasian individuals: CYP2C9*2. 0.143 and CYP2C9*3, 0.162 (P = 0.0001), Nearly 10% of the individuals studied are expected to metabolise deficiently CYP2C9 substrates. Conclusion: In some Caucasian populations the impact of the CYP2C9 polymorphism may be much higher than that estimated from genotyping studies published to date.

引用

页码：47 / 49

页数：3

共 17 条

[1] PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION
AGUNDEZ, JAG
LEDESMA, MC
LADERO, JM
BENITEZ, J
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) : 265 - 269
[2] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
Aithal, GP
Day, CP
Kesteven, PJL
Daly, AK
[J]. LANCET, 1999, 353 (9154) : 717 - 719
[3] Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
[4] Allelic and functional variability of cytochrome P4502C9
Bhasker, CR
Miners, JO
Coulter, S
Birkett, DJ
[J]. PHARMACOGENETICS, 1997, 7 (01): : 51 - 58
[5] BULPITT CJ, 1987, LANCET, V1, P494
[6] The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase
Crespi, CL
Miller, VP
[J]. PHARMACOGENETICS, 1997, 7 (03): : 203 - 210
[7] BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY
GOLDSTEIN, JA
DEMORAIS, SMF
[J]. PHARMACOGENETICS, 1994, 4 (06): : 285 - 299
[8] Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
Haining, RL
Hunter, AP
Veronese, ME
Trager, WF
Rettie, AE
[J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 333 (02) : 447 - 458
[9] Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
Ingelman-Sundberg, M
Oscarson, M
McLellan, RA
[J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (08) : 342 - 349
[10] Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations
Inoue, K
Yamazaki, H
Imiya, K
Akasaka, S
Guengerich, FP
Shimada, T
[J]. PHARMACOGENETICS, 1997, 7 (02): : 103 - 113

← 1 2 →